Suppression-Associated Immune Programs in Triple-Negative Breast Cancer Beyond Effector Enrichment: A Multi-Cohort Transcriptomic Analysis
- 1Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Faisal University, Al-Ahsa 36362, Saudi Arabia
- 2Research Center, King Fahad Specialist Hospital–Dammam, Eastern Health Cluster, Dammam 32253, Saudi Arabia
Abstract
High immune-cell infiltration does not guarantee effective anti-tumor immunity. Suppression of anti-tumor immunity may explain the variable prognosis and immunotherapy response of immune-inflamed triple-negative breast cancer (TNBC). We asked whether suppression-associated transcriptional signals merely accompanied effector-rich infiltration or retained a distinct association with TNBC across cohorts. Across TCGA-BRCA (discovery, n = 728), METABRIC (replication, n = 1980), and a Saudi exploratory cohort (n = 38), we evaluated a predefined effector immunity composite, an immunoregulatory cell-enrichment composite, and a six-gene suppressive myeloid-associated transcriptional score (CSF3R, OLR1, C5AR1, CLEC4E, ARG2, S100A8). In TCGA-BRCA, the effector immunity composite and six-gene score were both elevated and co-varied strongly (Spearman ρ = 0.66). Notably, the six-gene score remained associated with TNBC after adjustment for effector enrichment and age. The immunoregulatory cell-enrichment composite showed no significant difference, with opposing shifts among its components. In METABRIC, the main findings replicated and all three programs were elevated; the Saudi cohort showed concordant elevation. In a post hoc joint model with all three programs and age, the six-gene score remained positively associated with TNBC in TCGA-BRCA (OR 2.37) and METABRIC (OR 1.27). The six-gene score thus captured reproducible TNBC-associated variation beyond effector enrichment. Our findings motivate investigating whether this myeloid–effector interplay relates to TNBC prognosis and therapy response.
Related
- In Silico Single-Cell Transcriptomic Analysis Reveals Senescence-Associated Programs’ Progress Along the Normal–Adenoma–Carcinoma Sequence in Colorectal Cancer
- Transcriptomic profiling reveals conserved stage‐associated programs across gastrointestinal adenocarcinomas
- Integrated Transcriptomic and Biochemical Analyses Reveal Coordinated Suppression of ER-Associated Survival Signaling and Activation of ROS-Mediated Stress Responses by Oxidized Graphene Quantum Dots in Estrogen Receptor-Positive Breast Cancer
- Single-cell and bulk transcriptomic analysis of inflammation-metabolism programs and the tumor microenvironment of colorectal cancer liver metastasis
- Co-Enrichment of Desulfovibrio and Erysipelotrichaceae and Dysregulation of Multiple Amino Acid Pathways in HFpEF: Insights into TXG-Associated Metabolic Changes
BibTeX
@article{omair2026suppressionassociated,
title = {{Suppression-Associated Immune Programs in Triple-Negative Breast Cancer Beyond Effector Enrichment: A Multi-Cohort Transcriptomic Analysis}},
author = {Shorog Al Omair and Fahad Almsned},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = nov,
doi = {10.3390/ijms272210208},
url = {https://www.mdpi.com/1422-0067/27/22/10208},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Suppression-Associated Immune Programs in Triple-Negative Breast Cancer Beyond Effector Enrichment: A Multi-Cohort Transcriptomic Analysis
AU - Shorog Al Omair
AU - Fahad Almsned
PY - 2026
DA - 2026/11/14
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms272210208
UR - https://www.mdpi.com/1422-0067/27/22/10208
AB - High immune-cell infiltration does not guarantee effective anti-tumor immunity. Suppression of anti-tumor immunity may explain the variable prognosis and immunotherapy response of immune-inflamed triple-negative breast cancer (TNBC). We asked whether suppression-associated transcriptional signals merely accompanied effector-rich infiltration or retained a distinct association with TNBC across cohorts. Across TCGA-BRCA (discovery, n = 728), METABRIC (replication, n = 1980), and a Saudi exploratory cohort (n = 38), we evaluated a predefined effector immunity composite, an immunoregulatory cell-enrichment composite, and a six-gene suppressive myeloid-associated transcriptional score (CSF3R, OLR1, C5AR1, CLEC4E, ARG2, S100A8). In TCGA-BRCA, the effector immunity composite and six-gene score were both elevated and co-varied strongly (Spearman ρ = 0.66). Notably, the six-gene score remained associated with TNBC after adjustment for effector enrichment and age. The immunoregulatory cell-enrichment composite showed no significant difference, with opposing shifts among its components. In METABRIC, the main findings replicated and all three programs were elevated; the Saudi cohort showed concordant elevation. In a post hoc joint model with all three programs and age, the six-gene score remained positively associated with TNBC in TCGA-BRCA (OR 2.37) and METABRIC (OR 1.27). The six-gene score thus captured reproducible TNBC-associated variation beyond effector enrichment. Our findings motivate investigating whether this myeloid–effector interplay relates to TNBC prognosis and therapy response.
SN - 1422-0067
ER -